Clinical Trials Directory

Trials / Completed

CompletedNCT03150030

Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes

Status
Completed
Phase
Study type
Observational
Enrollment
42 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Twenty-one patients with insulin-treated type 2 diabetes with diabetic complications will be recruited to Part 1 of the study, a three-hour combined hyper- and hypoglycaemic clamp, along with a control group of twenty-one individuals with normal glucose tolerance matched for age, gender, and body mass index. Patients with type 2 diabetes will be scheduled for a three-week run-in period with LR and CGM prior to participation in Part 1. Only patients with a well-functioning loop-recorder and who can comply with CGM will be included. Patients with type 2 diabetes will continue in part 2 of the study, a one year observational study employing CGM and LR and clinical examination after 1, 3, 6, 9, and 12 months and an extended observation period of 2 years employing LR and clinical examination.

Conditions

Interventions

TypeNameDescription
OTHERCombined hyper- and hypoglycaemic clampDuring the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
DEVICELoop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)Implantation of a loop-recorder
DEVICEContinuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)Monitoring with a continuous glucose monitor

Timeline

Start date
2017-02-01
Primary completion
2020-01-06
Completion
2020-01-06
First posted
2017-05-11
Last updated
2020-11-02

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03150030. Inclusion in this directory is not an endorsement.